Press Releases

03.08.2018

Pfizer Announces Favorable Outcome of FDA Advisory Committee Meeting on XELJANZ® (tofacitinib) for Moderately to Severely Active Ulcerative Colitis

03.07.2018

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

03.05.2018

Dan R. Littman Elected to Pfizer’s Board of Directors

03.02.2018

Neofluidics Announces Collaboration with Pfizer Inc.

02.28.2018

Inserm announces research agreement with Pfizer Inc. to study rare neuromuscular disease

02.23.2018

Pfizer Receives Positive CHMP Opinion for Two Hematology Medicines, MYLOTARG™ and BOSULIF®

02.23.2018

Pfizer Announces Update on European Marketing Authorization Application for SUTENT® (sunitinib) in Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

02.23.2018

Albert Bourla Elected to Pfizer’s Board of Directors

02.14.2018

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis

02.12.2018

U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib

02.05.2018

Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer

01.30.2018

Pfizer Reports Fourth-Quarter and Full-Year 2017 Results